Background Alzheimer's disease (AD) is the most common neurodegenerative disease
worldwide, and an updated quantification of its impact on morbidity, disability, and mortality …

Alzheimer's disease (AD) is a prevalent neurodegenerative disease characterized by both
amnestic and non-amnestic clinical manifestations. It accounts for approximately 60-70% of …

Alzheimer's disease (AD) is a neurodegenerative disorder that affects millions of people
worldwide. Growing evidence suggests that the gut microbiome (GM) plays a pivotal role in …

Greater intake of whole grains, compared to refined grains, is consistently associated with a
reduced risk of cardiovascular disease and type 2 diabetes, both of which are associated …

Alzheimer's disease (AD) is a chronic, complex neurodegenerative disorder mainly
characterized by the irreversible loss of memory and cognitive functions. Different …

Neurodegenerative diseases have reached alarming numbers in the past decade.
Unfortunately, clinical trials testing potential therapeutics have proven futile. In the absence …

The core Alzheimer's disease (AD) cerebrospinal fluid (CSF) biomarkers; amyloid-β (Aß),
total tau (t-tau), and phosphorylated tau (p-tau181), are strong indicators of the presence of …

Dementia is a growing public health concern, with an estimated prevalence of 57 million
adults worldwide. Alzheimer's disease (AD) accounts for 60–80% of the cases. Clinical trials …

Background and Objectives Injured pericytes in the neurovascular unit release platelet-
derived growth factor β (PDGFRβ) into the CSF. However, it is not clear how pericyte injury …

The blood–brain barrier (BBB) is a unique and selective feature of the central nervous
system's vasculature. BBB dysfunction has been observed as an early sign of Alzheimer's …